You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline Snapshot as of

  • Discovery Projects
  • Phase 1
    13
  • Phase 2
    5
  • Phase 3
    20
  • Registration
    4
  • Total42
 
Compound Name
Indication
Phasesort descending
Submission Type
Compound Type
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06647263
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
ephrin-A4 (EFNA4) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06671008
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
cadherin 3, type 1, P-cadherin (placental) (CDH3)
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06688992
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
Antibody Drug Conjugate
Go to clinical trial
Cancer (Biologic)
Project advanced
Phase 1 New Molecular Entity Biologic
gedatolisib (PF-05212384)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Phosphatidyl inositol-3 kinase catalytic sub-unit a inhibitor / mammalian target of rapamycin inhibitor (PI3K/mTOR)
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06747143
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
chemokine (C-X-C motif) receptor 4 (CXCR4) Inhibitor
Go to clinical trial
Acute Myeloid Leukemia (Biologic) Phase 1 New Molecular Entity Biologic
PF-06747775
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
epidermal growth factor receptor (erythroblastic)
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
PF-06801591
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
programmed cell death 1 (PDCD1) Antagonist
Go to clinical trial
Cancer Immunotherapy (Biologic) Phase 1 New Molecular Entity Biologic
PF-06840003
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
indoleamine 2,3-dioxygenase 1 (IDO1) Inhibitor
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
PF-04136309
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
CCR2 (Chemokine receptor 2) Antagonist
Go to clinical trial
Pancreatic Cancer Phase 1 New Molecular Entity Small Molecule
PF-06883541
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
CD19 molecule Targeted Cytotoxicity CART
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-04518600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
OX40 receptor Agonist
Go to clinical trial
Cancer, Combo w/ avelumab (PD-L1) (Biologic) Phase 1 New Molecular Entity Biologic
PF-05082566
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CD137 Agonist
Go to clinical trial
Cancer (Biologic), Combo w/ Merck's Keytruda (PD-1, pembrolizumab), Combo w/ Kyowa Hakko Kirin's anti-CCR4 antibody (mogamulizumab) Phase 1 New Molecular Entity Biologic
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Hepatocellular Carcinoma Phase 2 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Merkel Cell Carcinoma (E.U.), Combo w/ PF-05082566 (41BB) for: Melanoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Triple-Negative Breast Cancer, *Cancer (Biologic) Phase 2 New Molecular Entity Biologic
glasdegib (PF-04449913)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Acute Myeloid Leukemia, *Cancer Phase 2 New Molecular Entity Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
Squamous Cell Carcinoma of the Head and Neck Phase 2 Product Enhancement Small Molecule
lorlatinib (PF-06463922)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
2nd Line ALK Non-Small Cell Lung Cancer (BREAKTHROUGH, ORPHAN - U.S.)
Project advanced
Phase 2 New Molecular Entity Small Molecule